The chronic kidney disease water intake trial: Protocol of a randomized controlled trial

Canadian Journal of Kidney Health and Disease

Volumn 4, Issue , 2017, Pages

  Clark, William F ^a   Huang, Shih Han ^a   Garg, Amit X ^a   Gallo, Kerri ^a   House, Andrew A ^a   Moist, Louise ^a   Weir, Matthew A ^a   Sontrop, Jessica M ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Chronic kidney disease; Copeptin; Estimated glomerular filtration rate; Randomized controlled trial; Vasopressin; Water intake

Indexed keywords

ALBUMIN; COPEPTIN; CREATININE;

ALBUMINURIA; ARTICLE; BEVERAGE; BLOOD ANALYSIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FLUID INTAKE; HUMAN; MALE; MICROALBUMINURIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINE OSMOLALITY; URINE VOLUME;

EID: 85032288331     PISSN: None     EISSN: 20543581     Source Type: Journal    
DOI: 10.1177/2054358117725106     Document Type: Article

References (78)

1. Vreeman RC, Carroll AE. Medical myths. BMJ. 2007; 335(7633):1288-1289.
2. Lette F, Dwyer JP. The fluid craze. Lancet. 2008;372(9641):782.
3. Valtin H. "Drink at least eight glasses of water a day." Really? Is there scientific evidence for "8 x 8"? Am J Physiol Regul Integr Comp Physiol. 2002;283(5):R993-1004.
4. Clark WF, Sontrop JM, Huang S-H, Moist L, Bouby N, Bankir L. Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol. 2016;43(4):281-292.
5. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155:839-843.
6. Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Lieske JC. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. J Nephrol. 2015;29(2):211-219.
7. Dawson CH, Tomson CRV. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med. 2012;12(5):467-471.
8. Pearle MS, Goldfarb DS, Assimos DG, et al; for American Urological Association. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324.
9. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659-667.
10. Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17(8):2220-2227.
11. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102-108.
12. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1140-1150.
13. Wang CJ, Creed C, Winklhofer FT, Grantham JJ. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol. 2011;6:192-197.
14. Higashihara E, Nutahara K, Tanbo M, et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant. 2014;29(9):1710-1719.
15. Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5(4):693-697.
16. Wesseling C, Crowe J, Hogstedt C, Jakobsson K, Lucas R, Wegman DH. Resolving the enigma of the mesoamerican nephropathy: a research workshop summary. Am J Kidney Dis. 2014;63(3):396-404.
17. Weiner DE, McClean MD, Kaufman JS, Brooks DR. The Central American epidemic of CKD. Clin J Am Soc Nephrol. 2013;8(3):504-511.
18. Laws RL, Brooks DR, Amador JJ, et al. Changes in kidney function among Nicaraguan sugarcane workers. Int J Occup Environ Health. 2015;21(3):241-250.
19. Laws RL, Brooks DR, Amador JJ, et al. Biomarkers of kidney injury among Nicaraguan sugarcane workers. Am J Kidney Dis. 2015;67(2):209-217.
20. Glaser J, Lemery J, Rajagopalan B, et al. Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy. Clin J Am Soc Nephrol. 2016;11(8):1472-1483.
21. Hansen AL, Bi P, Ryan P, Nitschke M, Pisaniello D, Tucker G. The effect of heat waves on hospital admissions for renal disease in a temperate city of Australia. Int J Epidemiol. 2008;37(6):1359-1365.
22. Bobb JF, Obermeyer Z, Wang Y, Dominici F. Cause-specific risk of hospital admission related to extreme heat in older adults. JAMA. 2014;312(24):2659-2667.
23. Fletcher BA, Lin S, Fitzgerald EF, Hwang S-A. Association of summer temperatures with hospital admissions for renal diseases in New York State: a case-crossover study. Am J Epidemiol. 2012;175(9):907-916.
24. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis. 2003;41:962-971.
25. Clark WF, Sontrop JM, Macnab JJ, et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol. 2011;6(11):2634-2641.
26. Sontrop JM, Dixon SN, Garg AX, et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol. 2013;37:434-442.
27. Shoham DA, Durazo-Arvizu R, Kramer H, et al. Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999-2004. PLoS ONE. 2008;3:e3431.
28. Saldana TM, Basso O, Darden R, Sandler DP. Carbonated beverages and chronic kidney disease. Epidemiology. 2007; 18(4):501.
29. Yuzbashian E, Asghari G, Mirmiran P, Zadeh-Vakili A, Azizi F. Sugar-sweetened beverage consumption and risk of incident chronic kidney disease: Tehran lipid and glucose study. Nephrology. 2016;21(7):608-616.
30. Bomback AS, Derebail VK, Shoham DA, et al. Sugarsweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010;77(7):609-616.
31. Karalius VP, Shoham DA. Dietary sugar and artificial sweetener intake and chronic kidney disease: a review. Adv Chronic Kidney Dis. 2013;20(2):157-164.
32. Cheungpasitporn W, Thongprayoon C, O'Corragain OA, Edmonds PJ, Kittanamongkolchai W, Erickson SB. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19(12):791-797.
33. Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45(8):911-916.
34. Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol. 2013;8(8):1389-1395.
35. Nguyen NU, Dumoulin G, Henriet MT, Regnard J. Increase in urinary calcium and oxalate after fructose infusion. Horm Metab Res. 1995;27(3):155-158.
36. Fox IH, Kelley WN. Studies on the mechanism of fructoseinduced hyperuricemia in man. Metabolism. 1972;21(8):713-721.
37. Clark WF, Sontrop JM, Huang SH, et al. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open. 2013;3(12):e003666.
38. Sontrop JM, Huang S-H, Garg AX, et al. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open. 2015;5(11):e008634.
39. Tangri N, Grams ME, Levey AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164-174.
40. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(Suppl 1):S1-266.
41. Spigt M, van Schayck O, Knipschild P, et al. Is it possible to improve elderly male bladder function by having them drink more water? A randomized trial of effects of increased fluid intake/urine output on male lower urinary tract function. Urology. 2006;68(5):1031-1036.
42. Spigt MG, Knottnerus JA, van de Beek C, van Kerrebroeck PE, van Amelsvoort LG, van Schayck CPO. Short-term effects of increased urine output on male bladder function and lower urinary tract symptoms. Urology. 2004;64(3):499-503.
43. Spigt MG, Knottnerus JA, Westerterp KR, Olde Rikkert MG, Schayck CP. The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men. J Am Geriatr Soc. 2006;54:438-443.
44. Akers JD, Cornett RA, Savla JS, Davy KP, Davy BM. Daily self-monitoring of body weight, step count, fruit/vegetable intake, and water consumption: a feasible and effective longterm weight loss maintenance approach. J Acad Nutr Diet. 2012;112(5):685-692.e2.
45. Hays RD, Kallich J, Mapes D, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF TM), Version 1.3 [Internet]. RAND Corporation; 1997. http://www.rand.org/pubs/papers/P7994.html. Accessed July 25, 2017
46. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329-338.
47. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
48. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
49. Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99:4656-4663.
50. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43-49.
51. Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36(11):3639-3645.
52. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens. 2010;19:499-504.
53. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88:561-567.
54. Methven S, Macgregor MS, Glas F, et al. Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. Am J Kidney Dis. 2011;57(1):21-28.
55. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol. 2012;8(5):301-306.
56. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med. 2005;24(7):993-1007.
57. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-1360.
58. Carpenter JR, Kenward MG. Missing data in randomised controlled trials-a practical guide. 2007. http://citeseerx.ist. psu.edu/viewdoc/download?doi=10.1.1.468.9391&rep=rep1 &type=pdf. Accessed January, 2017.
59. Garg AX, Kurz A, Sessler DI, et al. Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. JAMA. 2014;312(21):2254-2264.
60. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z. Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol. 2015;10(11):1946-1955.
61. Perkins RM, Bucaloiu ID, Kirchner HL, Ashouian N, Hartle JE, Yahya T. GFR decline and mortality risk among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1879-1886.
62. Kovesdy CP, Coresh J, Ballew SH, et al. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol. 2016;27(8):2447-2455.
63. Naimark DMJ, Grams ME, Matsushita K, et al. Past decline versus current eGFR and subsequent mortality risk. J Am Soc Nephrol. 2016;27(8):2456-2466.
64. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589.
65. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-272.
66. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88(5):950-957.
67. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol. 2004;15(5):1363-1364.
68. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004;15(5):1300-1306.
69. Torres VE. Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int. 2009;76(9):925-928.
70. Perico N, Zoja C, Corna D, et al. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 2009;76:960-967.
71. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol. 1990;258(4, pt 2): F973-f979.
72. Sugiura T, Yamauchi A, Kitamura H, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-ß. Kidney Int. 1999;55(5):1800-1810.
73. Meijer E, Boertien WE, Zietse R, Gansevoort RT. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2011;34(4):235-244.
74. Bouby N, Fernandes S. Mild dehydration, vasopressin and the kidney: animal and human studies. Eur J Clin Nutr. 2003;57(Suppl 2):S39-S46.
75. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418.
76. Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012;27(11):4131-4137.
77. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55(19):2096-2106.
78. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (Copeptin) as a novel and prognostic marker in acute myocardial infarction. Circulation. 2007;115(16):2103-2110.